||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
E-Therapeutics Share Discussion Threads
Showing 201 to 222 of 225 messages
|Founder leaving cannot be good :(|
|timbo, a good point. There was not a resolution on directors' remuneration. I guess it is not required for AIM companies.|
|Hi gnnmartin, thank you for the helpful writeup.
Interesting to see the Searchbolt acquisition as defensive, and especially if the focus is now on the platform and partnering deals.
|Nigel, could it be anything to do with Malcolm's ridiculously large remuneration? He has to be the best paid CEO (by a mile) for any sub £100m life sciences company on AIM.
Was it a similar voting pattern for the resolutions concerning the remuneration report and remuneration policy?|
|I went to the AGM today. Nothing new to report. I went to ask for more information about the proposal to buy back Searchbolt that TW was so scathing about.
Iain Ross, non-exec chairman appointed January this year, told me that it was his guidance that triggered the action. Searchbolt had not been commercially successful and had some creditors that had potential spoiling power should ETX be successful in signing up a major pharmaceutical partner. Iain thought the possibility a patent troll like action from 3rd parties would be sufficiently off-putting to a major pharma, and it was worth (effectively) buying out the creditors.
I accept the explanation, though I don't know enough about the industry to make any informed judgement. I assume the concern is a consequence of the change of focus mentioned in the annual report: "Since originally identifying our first lead development compounds, substantial investment has enabled us to accelerate the development and expand the Company’s discovery capabilities and infrastructure. The platform is now the core focus for the business as it provides fast and accurate data enabling the identification of highly potent novel compounds which have the potential to be ‘game changers’ in established multiple, billion dollar markets.
One oddity came out of the meeting, possibly of no significance. The 4th motion was to re-elect Malcolm Young as director, and 3 proxy voters holding 47.3m votes between them abstained. I asked if there was any background to this, but was told no. Usually a deliberate abstention (as opposed to simply not bothering to vote) expresses some mild dissatisfaction or concern. With that number of votes being cast, one of the 3 abstainers was either Woodford or Aviva. Malcolm seems pretty central to the company strategy.|
|Cheers gooner108, bit of a punt on this one but could be big optionality|
|Tom W.[Shareprophets] has a low opinion of this share. Worth checking.|
|Agree. Looks like decent potential.|
|Thanks for the link ProactiveST. Good credible interview, very confident CEO with exciting propects for the future of the company.|
|Video interview with Malcolm Young
e-Therapeutics plc (LON:ETX) is targeting partners to accelerate the development of its drug discovery engine, it told investors on Tuesday.
Malcolm Young, chief executive, tells Proactive that “making alliances with much larger companies is absolutely our foreground so that’s where we need to go, that’s where our frontier is, that’s where we need to make the advances.”
He adds “commercialisation as a focus in the company has really grown in significance in this last year,” and that the firm is looking for partnerships as a way to recognise the commercial value of both late stage and early stage products.|
|someone knows something, we'll know tomorrow!|
|down 21pc- any idea why?- this one has got Woodford invested and a string of well known managers!|
|Not an investor here but have seen a few presentations at Mayfair. They looked interesting at that time. Today's RNS seems weird to me. It seemed to be presented as good news when it is probably anything but. A massive drop first thing and any bottom feeders would have done well. I can't see given the wooliness of the RNS any great upside on this so I confess I am slightly bemused by the share price partial recovery since the opening.|
|Video interview with CEO Young
E-Therapeutics (LON:ETX) chief executive Malcolm Young tells Proactive that the firm has hit the “sweet spot” on the drug candidate ETS6103 following its latest test results.
The Phase IIb study, which was a larger study at a lower dose showed the drug was a little bit off the efficacy of its rival amitriptyline, but was still effective.
But the firm has previously completed a Phase IIa study on ETS6103, which was carried out on a small number of patients at a higher dose, showing the drug had the same efficacy as its closest rival.
Young says that the drug has a “cleaner profile” than amitriptyline, and adds that “across the two studies, we are pleased.”|
|Yes. Disappointing results.ETS6103 confirmed as effective in treating second line depressive conditions but not as effective as tricyclics (which is what was hoped).Tricyclics have more side effects and so they hold onto this as giving ETS6103 some value; but overall the results are disappointing IMO.|
|Eh? can anyone decipher this?
|Malcolm Young, CEO of e-Therapeutics, will be presenting to investors at the Chesterfield Hotel in Mayfair on the 24th September from 6pm. To register to attend, please click here: http://tinyurl.com/ot266cz|
looking very positive :-)|
|Woodford and Henderson buying, the institutions are topping up, they must think there are good times ahead. Have been a long time holder and looking forward to the next couple of years. onward and upward|
|Tolmers, re your question on post #111
I sold out in the low thirties a few weeks ago (Lorraine still holds).
The current market cap of £100m seems a bit on the high side based on the likely risk adjusted value for the two drugs currently in the clinic, but having said that, I find it very difficult to value the other part of the business, i.e. their proprietary Network Pharmacology technology which could be worth hundreds of millions of dollars to a large pharma looking to get a fast track into the technology. I'm not sure exactly how validated the network technology is, they are claiming that their hit rate is orders of magnitude greater than conventional screening methods, but I think it really does need to be validated by one or more clinical successes before assigning a potential value.|
I must admit I'm now a bit confused whether the RNS was reiterating previous, or emphasising the continuation of promising results.|
|At least the RNS didn't say that the company had no idea why there is a recent rise in its share price. All it did was reiterate what has already been communicated. Hopefully the press will make a comment tomorrow morning and we'll see if this continues upwards or the profit taking will take hold|